VASCULOX, INC.

Company Information

Company Name
VASCULOX, INC.
Address
4320 Forest Park Avenue
Suite 303
SAINT LOUIS, MO, -
Phone
n/a
URL
http://www.vasculox.com
DUNS
794768551
Number of Employees
7
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$479,423.00
2
SBIR Phase II
$2,665,514.00
2
STTR Phase I
$497,398.00
2
Chart code to be here

Award List

  1. Development of a humanized anti-CD47 antibody for treatment of tissue ischemia.

    Amount: $197,711.00

    DESCRIPTION (provided by applicant): Nitric oxide (NO) is a critical regulator of cardiovascular physiology, coordinating the activities of the endothelium, the vessel wall and circulating cells to op ...

    STTR Phase I 2009 Department of Health and Human Services
  2. Treatment of Transplant Reperfusion with an Anti-CD47 Antibody

    Amount: $203,191.00

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die ...

    SBIR Phase I 2009 Department of Health and Human Services
  3. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    Amount: $276,232.00

    DESCRIPTION (provided by applicant): Organ transplantation is one of the great success stories of modern medicine. However, the supply of suitable organs lags far behind the need and many patients die ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Treatment of Transplant Reperfusion with CD47 antibody

    Amount: $1,533,751.00

    DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgica ...

    SBIR Phase II 2012 Department of Health and Human Services
  5. Tumor-toxic CD47 mAb therapy for leukemia: a proof of concept study

    Amount: $299,687.00

    DESCRIPTION (provided by applicant): CD47 has emerged as a novel therapeutic target in hematologic cancers. Leukemias expressing the highest levels of CD47 have the worst prognosis. Increased CD47 exp ...

    STTR Phase I 2013 Department of Health and Human Services
  6. Anti-CD47 mAb Therapy to Improve Kidney Transplantation

    Amount: $1,131,763.00

    DESCRIPTION (provided by applicant): Organ transplantation is a lifesaving option for those with end stage renal disease. In spite of many improvements in organ procurement, transplant procedures and ...

    SBIR Phase II 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government